|
Company:
|
INSULET CORP (PODD)
|
|
Form Type:
|
4
|
|
Filing Date:
|
2/19/2021
|
|
CIK:
|
0001145197
|
|
Address:
|
100 NAGOG PARK
|
|
City, State, Zip:
|
ACTON, Massachusetts 01720
|
|
Telephone:
|
978-600-7000
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$288.13
|
Change:
3.41 (1.20%)
|
Trade Time:
Apr 13
|
Market Cap:
$19.04B
|
|
|
|
|
|
|
Description of Business
|
|
Insulet Corporation ("we" or the "Company") is primarily engaged in the
development, manufacture and sale of its proprietary Omnipod® System, a
continuous insulin delivery system for people with insulin-dependent diabetes,
which we have been selling since 2005. The Omnipod System includes: the Omnipod
Insulin Management System ("Omnipod") and the Omnipod DASHTM Insulin Management
System ("Omnipod DASH" or "DASH"), our digital mobile Omnipod platform. In
addition to the diabetes market space, we have partnered with pharmaceutical and
biotechnology companies to tailor the Omnipod System technology platform for the
delivery of subcutaneous drugs across other therapeutic areas. Most of our drug
delivery revenue consists of sales of pods to Amgen for use in the Neulasta®
Onpro® kit, a delivery system for Amgen's white blood cell booster to help
reduce the risk of infection after intense chemotherapy.
|
|
|
|